ApoLive-Glo™ Multiplex Assay

G6410_ApoLive-Glo--Multiplex-Assay--10ml_3
View information on global supply logistics
customize-this-small

Measure Viability and Apoptosis in the Same Sample Well

  • Accurately determine mechanism of cell death in less time, with less sample
  • Easy to implement using a simple sequential 'add-mix-measure' protocol
  • Adaptable to meet various throughput needs

Size

Catalog number selected: G6410

$ 582.00
Your price:
Add to Cart
This product is discontinued
Add to Helix
This product is available under our Early Access program - Learn More
This product is available under our Catalog (FT) program - Learn More
ApoLive-Glo™ Multiplex Assay
10ml
$ 582.00
Your price: Log in
Change Configuration

Two Technologies Combined in One Effective Assay

The ApoLive-Glo™ Multiplex Assay measures both the number of viable cells as a marker of cytotoxicity and caspase activation as a marker of apoptosis within a single assay well to determine the mechanism of cell death. The first part of the assay measures the activity of a protease marker of cell viability. The live-cell protease activity is restricted to intact viable cells and is measured using a fluorogenic, cell-permeant, peptide substrate (glycyl-phenylalanyl-amino fluorocoumarin; GF-AFC). The substrate enters intact cells, where it is cleaved by the live-cell protease activity to generate a fluorescent signal proportional to the number of living cells. This live-cell protease becomes inactive upon loss of cell membrane integrity and leakage into the surrounding culture medium.

The second part of the assay uses the Caspase-Glo® Assay technology to detect caspase activation, a key biomarker of apoptosis. The Caspase-Glo® Assay provides a luminogenic caspase-3/7 substrate, which contains the tetrapeptide sequence DEVD, in a reagent optimized for caspase activity, luciferase activity and cell lysis. Adding the Caspase-Glo® 3/7 Reagent in an 'add-mix-measure' format results in cell lysis, followed by caspase cleavage of the substrate and generation of a 'glow-type' luminescent signal produced by luciferase. Luminescence is proportional to the amount of caspase activity present.

Predictive Measures of Viability and Apoptosis in the Same Sample Well

8141MA-W

Ionomycin treatment of Jurkat cells for 6 hours results in dose-dependent decrease in viability and increase in cytotoxicity with no caspase-3/7 activation, consistent with primary necrosis.

8140MA-W

ApoTox-Glo™ Triplex Assay with suspension Jurkat cells treated with staurosporine. Staurosporine treatment for 6 hours results in a dose-dependent decrease in viability and increase in cytotoxicity with an increase in caspase-3/7 activity consistent with apoptosis.

Specifications

You are viewing: G6410 Change Configuration

What's in the box?

Item Part # Size

GF-AFC Substrate

G608A 1 × 10μl

Assay Buffer

G610A 1 × 10ml

Caspase-Glo® 3/7 Buffer

G810A 1 × 10ml

Caspase-Glo® 3/7 Substrate

G811A 1 × 1 bottle

Certificate of Analysis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

 

Patents and Disclaimers

U.S. Pat. Nos. 7,148,030, 7,384,758, 7,666,987 and 8,071,328 and other patents and patents pending.

U.S. Pat. Nos. 7,416,854, 7,553,632 and other patents pending.

Specifications

You are viewing: G6411 Change Configuration

What's in the box?

Item Part # Size

GF-AFC Substrate

G608B 1 × 50μl

Assay Buffer

G610A 2 × 10ml

Caspase-Glo® 3/7 Buffer

G810A 5 × 10ml

Caspase-Glo® 3/7 Substrate

G811A 5 × 1 bottle

Certificate of Analysis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

 

Patents and Disclaimers

U.S. Pat. Nos. 7,148,030, 7,384,758, 7,666,987 and 8,071,328 and other patents and patents pending.

U.S. Pat. Nos. 7,416,854, 7,553,632 and other patents pending.

Let's find the product that meets your needs.

Talk to a Scientist

scientist-uk-manos

Manos

UK